Published in J Neural Transm (Vienna) on August 04, 2009
Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol (2012) 1.42
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement (2014) 1.28
Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front Aging Neurosci (2013) 0.94
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. Alzheimers Res Ther (2015) 0.91
Increased concentration of the CSF Tau protein and its phosphorylated form in the late juvenile metachromatic leukodystrophy form: a case report. J Neural Transm (Vienna) (2012) 0.80
Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: a pilot study. J Neural Transm (Vienna) (2012) 0.80
Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation. Front Neurol (2015) 0.77
Confirmation rate of blinded (99m)Tc-SPECT compared to neurochemical dementia biomarkers in CSF in patients with Alzheimer disease. J Neural Transm (Vienna) (2010) 0.77
Characterization of acid sphingomyelinase activity in human cerebrospinal fluid. PLoS One (2013) 0.76
Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis? J Alzheimers Dis (2015) 0.75
Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. J Alzheimers Dis (2015) 0.75
Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease. Int J Alzheimers Dis (2010) 0.75
Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging (1998) 5.05
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology (2002) 1.84
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry (2008) 1.54
Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging (2004) 1.48
Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol (1995) 1.46
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem (2007) 1.28
International quality control survey of neurochemical dementia diagnostics. Neurosci Lett (2006) 1.26
Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol (2001) 1.18
Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci (2004) 1.13
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (Vienna) (2009) 1.10
Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener Dis (2009) 1.05
Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging (2006) 1.00
Neurochemical dementia diagnostics: State of the art and research perspectives. Proteomics (2008) 0.94
Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia. J Neural Transm (Vienna) (2008) 0.80
Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci Lett (1996) 0.79
Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci Lett (1997) 0.79
[Sensitivity of neurochemical dementia diagnostics in CSF compared to 99mTc-SPECT in Alzheimer's dementia]. Fortschr Neurol Psychiatr (2009) 0.77
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem (2006) 3.03
The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J (2012) 2.72
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res (2010) 2.45
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43
Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES). Arch Gynecol Obstet (2013) 2.06
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Managing an effective treatment for neuroleptic malignant syndrome. Crit Care (2007) 1.73
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem (2006) 1.54
Use-dependent inhibition of synaptic transmission by the secretion of intravesicularly accumulated antipsychotic drugs. Neuron (2012) 1.51
Epigenetic DNA hypermethylation of the HERP gene promoter induces down-regulation of its mRNA expression in patients with alcohol dependence. Alcohol Clin Exp Res (2006) 1.51
Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord (2006) 1.49
Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis (2009) 1.49
Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging (2004) 1.48
DNA hypermethylation of the alpha synuclein promoter in patients with alcoholism. Neuroreport (2005) 1.46
Drug-induced psychosis after long-term treatment with levetiracetam. Can J Psychiatry (2004) 1.46
Repetitive transcranial magnetic stimulation influences mood in healthy male volunteers. J Psychiatr Res (2011) 1.46
Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med (2013) 1.36
Therapeutic approaches to Alzheimer's disease. Brain (2006) 1.34
Global DNA methylation is influenced by smoking behaviour. Eur Neuropsychopharmacol (2008) 1.29
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem (2007) 1.28
Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis (2004) 1.27
International quality control survey of neurochemical dementia diagnostics. Neurosci Lett (2006) 1.26
Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated. Mol Neurodegener (2010) 1.25
CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 1.25
Non-drug therapies for dementia: an overview of the current situation with regard to proof of effectiveness. Dement Geriatr Cogn Disord (2003) 1.17
Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J Neurochem (2005) 1.14
Association of SORL1 gene variants with Alzheimer's disease. Brain Res (2009) 1.14
Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. J Biol Chem (2008) 1.13
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem (2007) 1.13
Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci (2004) 1.13
Promoter specific methylation of the dopamine transporter gene is altered in alcohol dependence and associated with craving. J Psychiatr Res (2008) 1.10
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (Vienna) (2009) 1.10
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging (2007) 1.10
Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults. J Neural Transm (Vienna) (2010) 1.09
Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord (2009) 1.08
A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats. Brain (2013) 1.07
Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol (2010) 1.05
Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation. Am J Pathol (2012) 1.04
Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci Lett (2008) 1.04
Daily variations of homocysteine concentration may influence methylation of DNA in normal healthy individuals. Chronobiol Int (2007) 1.03
Optimized data preprocessing for multivariate analysis applied to 99mTc-ECD SPECT data sets of Alzheimer's patients and asymptomatic controls. J Cereb Blood Flow Metab (2010) 1.03
Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics (2008) 1.03
Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord (2005) 1.03
Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol (2003) 1.02
Homocysteine in tear fluid of patients with pseudoexfoliation glaucoma. J Glaucoma (2007) 1.02
HUPO Brain Proteome Project: summary of the pilot phase and introduction of a comprehensive data reprocessing strategy. Proteomics (2006) 1.02
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02
Alpha-synuclein protein levels are increased in alcoholic patients and are linked to craving. Alcohol Clin Exp Res (2005) 1.01
Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry (2004) 1.01
Unchanged survival rates of 14-3-3gamma knockout mice after inoculation with pathological prion protein. Mol Cell Biol (2005) 1.01
Ghrelin levels are increased in alcoholism. Alcohol Clin Exp Res (2005) 1.00
Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging (2006) 1.00
Elevated alpha synuclein mRNA levels are associated with craving in patients with alcoholism. Biol Psychiatry (2004) 1.00
Auricular transcutaneous electrical nerve stimulation in depressed patients: a randomized controlled pilot study. J Neural Transm (Vienna) (2012) 0.99
Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett (2004) 0.99
Quantitative modeling of selective lysosomal targeting for drug design. Eur Biophys J (2008) 0.99
Epigenetic dysregulation of dopaminergic genes in eating disorders. Int J Eat Disord (2010) 0.99
Disentangling structural brain alterations associated with violent behavior from those associated with substance use disorders. Arch Gen Psychiatry (2011) 0.98
Cerebrospinal fluid leakage--reliable diagnostic methods. Clin Chim Acta (2011) 0.98
N-methyl-D-aspartate 2b receptor subtype (NR2B) promoter methylation in patients during alcohol withdrawal. J Neural Transm (Vienna) (2009) 0.98
DNA methylation of the POMC gene promoter is associated with craving in alcohol dependence. J Neural Transm (Vienna) (2010) 0.97
Brain morphometry reproducibility in multi-center 3T MRI studies: a comparison of cross-sectional and longitudinal segmentations. Neuroimage (2013) 0.97
Secretory sphingomyelinase in health and disease. Biol Chem (2015) 0.97
Microstructural abnormalities of the posterior thalamic radiation and the mediodorsal thalamic nuclei in females with anorexia nervosa--a voxel based diffusion tensor imaging (DTI) study. J Psychiatr Res (2012) 0.97
Cortical activity associated with auditory hallucinations. Neuroreport (2004) 0.96
Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome. Dement Geriatr Cogn Disord (2007) 0.96
Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem (2007) 0.96
Hippocampal volume differences between healthy young apolipoprotein E ε2 and ε4 carriers. J Alzheimers Dis (2011) 0.96
Systematic heterogeneity of fractional vesicle pool sizes and release rates of hippocampal synapses. Biophys J (2011) 0.96
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics (2007) 0.96
CNS BOLD fMRI effects of sham-controlled transcutaneous electrical nerve stimulation in the left outer auditory canal - a pilot study. Brain Stimul (2013) 0.96
C677T variant in the methylentetrahydrofolate reductase gene is a genetic risk factor for primary open-angle glaucoma. Am J Ophthalmol (2005) 0.95
Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry (2003) 0.95